Aug 6 (Reuters) - Prothena Corporation PLC PRTA.O:
PROTHENA ANNOUNCES THAT NOVO NORDISK WILL ADVANCE CORAMITUG (FORMERLY PRX004) INTO PHASE 3 DEVELOPMENT FOR ATTR AMYLOIDOSIS WITH CARDIOMYOPATHY
PROTHENA CORPORATION: UNDER AGREEMENT, CO IS ELIGIBLE TO RECEIVE UP TO $1.2 BILLION DOLLARS UPON ACHIEVEMENT OF CLINICAL DEVELOPMENT & SALES MILESTONES